| 1 |
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma |
Multiple Myeloma |
Drug: Daratumumab|Drug: Bortezomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Cilta-cel|Drug: Cyclophosphamide|Drug: Fludarabine |
European Myeloma Network|Janssen Research & Development, LLC |
Phase 3 |
NCT05257083 |
2023-08-01 |
| 2 |
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) |
Acute Myeloid Leukemia |
Biological: WU-NK-101 |
Wugen, Inc. |
Phase 1 |
NCT05470140 |
2023-07-01 |
| 3 |
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) |
Systemic Lupus Erythematosus |
Drug: ianalumab|Drug: placebo |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05624749 |
2023-04-21 |
| 4 |
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma |
Multiple Myeloma |
Drug: Cevostamab|Drug: XmAb24306|Drug: Tocilizumab |
Genentech, Inc. |
Phase 1 |
NCT05646836 |
2023-03-17 |
| 5 |
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) |
Primary Immune Thrombocytopenia (ITP) |
Biological: Ianalumab|Drug: Placebo|Drug: Corticosteroids |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05653349 |
2023-03-06 |
| 6 |
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours |
Colorectal Cancer|Gastroesophageal Cancer|Ovarian Cancer |
Biological: IVX037 |
ImmVirx Pty Ltd |
Phase 1 |
NCT05427487 |
2023-02-17 |
| 7 |
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma |
High-risk Large B-cell Lymphoma (LBCL) |
Biological: Axicabtagene Ciloleucel|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Etoposide|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone |
Kite, A Gilead Company|Gilead Sciences |
Phase 3 |
NCT05605899 |
2023-02-10 |
| 8 |
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy |
Peanut Allergy|Peanut Hypersensitivity|Peanut-Induced Anaphylaxis|Immune System Diseases |
Biological: PVX-108|Biological: Placebo |
Aravax Pty Ltd |
Phase 2 |
NCT05621317 |
2023-02-09 |
| 9 |
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
Diffuse Large B-Cell Lymphoma |
Drug: Epcoritamab|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone |
AbbVie|Genmab |
Phase 3 |
NCT05578976 |
2023-02-08 |
| 10 |
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥0% (MK-3475-D46) |
Carcinoma, Non-Small-Cell Lung |
Biological: Sacituzumab Govitecan|Biological: Pembrolizumab |
Merck Sharp & Dohme LLC|Gilead Sciences |
Phase 3 |
NCT05609968 |
2023-02-06 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.